Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Biogen

These two biotechs are going after a significant market: Alzheimer's.

Better Buy: Biogen vs. Cassava Sciences

San Francisco, California--(Newsfile Corp. - September 3, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading sta

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending

Boston, Massachusetts--(Newsfile Corp. - September 3, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive. ...

SAVA DEADLINE: Berman Tabacco Alerts Investors with Losses In Excess of $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. Class Action

Cassava Sciences Inc.'s Chief Executive Remi Barbier said on Friday that recent allegations of fraud were “false and misleading” and were a result of investor interests to drive down the price of the biotechnology company's stock.

Cassava Sciences CEO says ‘enormous profit motive' behind N.Y. law firm's fraud allegations

Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based on manipulation and misrepresentation. Related:   Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy.

Cassava CEO Goes Offensive Over Data Allegations

NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a clinical

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.

Fraud Allegations Are Unlikely to Keep Cassava Stock Down

RADNOR, Pa., Sept. 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ:  SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA

AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a public statement regarding recent allegations made against the Company.

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops. The post Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations appeared first on InvestorPlace.

Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations

Investing in biotech stocks can pay off big, but only if their research pans out. Pay attention to the risk-reward ratio -- and control your greed.

Here's How You Handle a Volatile Stock Like Cassava Sciences

Boston, Massachusetts--(Newsfile Corp. - September 1, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive...

SAVA ALERT: Berman Tabacco Announces Approaching Lead Plaintiff Deadline for Cassava Sciences, Inc. Investors with Losses in Excess of $100,000

New York, New York--(Newsfile Corp. - September 1, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...

SAVA INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.

SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded

BlueCity Holdings Limited

Live Ventures

NEW YORK, NY / ACCESSWIRE / September 1, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLCT, LIVE and SAVA

SAN DIEGO--(BUSINESS WIRE)-- #Cassavacase--The suit alleges defendants issued false statements concerning Cassava business and prospects, resulting in its stock trading at inflated prices.

SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

SAN DIEGO & AUSTIN, Texas--(BUSINESS WIRE)---- $SAVA #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 2, 2021 and August 24, 2021, for violations of the Securities Exchange Act of 1934. Cassava is a biotechnology company engaged in the development of drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simuf

SHAREHOLDER ALERT: Robbins LLP Announces that Cassava Sciences, Inc. (SAVA) is Being Sued for Misleading Shareholders

San Francisco, California--(Newsfile Corp. - August 31, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and failed to...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded

NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (Nasdaq: SAVA) from February 2, 2021 through August 24, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Western District of Texas alleges violations of the Securities Act of 1934.

SAVA INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

Short sellers have raked in millions betting against drugmaker and meme stock Cassava Sciences. But some retail investors say they're buying the dip.

Short sellers betting against meme stock Cassava have made $100 million over the past month as the stock has struggled

BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). Cassava investors have until October 26, 2021 to file a lead plaintiff motion. Investors suffering losses on their Cassava investments are encouraged to contact the Law Offices of Howard G

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors

Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result.

Wait to See How the Cassava Sciences Allegations Pan Out

NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company")  NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sava.

SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Cassava Sciences, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

SAN FRANCISCO, Aug. 31, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.     Class Period: Feb. 2, 2021 – Aug. 24, 2021 Lead Plaintiff Deadline: Oct. 26, 2021 Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com                                                844-916-0895 Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Cassava and senior management made false and misleading statements and failed to disclose that the quality and integrity of the scientific data supporting the company's claims of efficacy for its Alzheimer's drug (simufilam) were overstated and biased.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed

News for Cassava Sciences Inc Stock (SAVA)